ARCHIVES

FDA advisors vote against recommending Johnson & Johnson’s Zarnestra for treatment of AML in the elderly.

This article is from The Cancer Letter archive.

Vol. 31 No. 18 | May 6, 2005

Download PDF Visit The Full Archive

Related Articles

Lower Stomach Cancers Increasing In Younger U.S. Whites, Study Finds

May 28, 2010

PhRMA Tightens DTC Restrictions, But Dingell Says It’s Not Enough.

December 12, 2008

NCI To Study Whether It Gets The Most From Advisors.

March 8, 2002

HHS Agency Says It Has No Jurisdiction And No Cause to Act on I-ELCAP Allegations

March 2, 2012

Centers Got $35 Million In NIH Construction $$; Send In Applications, Branch Chief Says

July 24, 1992

Advisors approve NCI’s revised plan for $104-million proteomics research program.

July 8, 2005